arrow_back Back Filing freshness 10-Q Q3 FY2026 SEC EDGAR

RHYTHM PHARMACEUTICALS, INC.

RYTM
$105.17 ▲ +0.02 (+0.02%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
43 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
18
Health
Poor
Bearish
auto_awesome

Analytical Summary

RHYTHM PHARMACEUTICALS, INC. faces fundamental challenges with weakness in Return on Common Equity (%) and Profit Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $7.3B
Dividend Yield —
Revenue Growth 79.6% ↗
Op. Margin -42.6% ↗
ROIC -22.7% ↗
FCF / Share $-0.04 ↗
Trailing P/E —
Price / Book 82.9x
FCF Yield —
Debt / Equity 1.00
info Valuation on last close. End-of-day price, Nov 5, 2026.

43-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$92.13M
↑ +79.6% —
Net Income Profit after all expenses
$-55.64M
↓ -12.4% —
Operating Margin Operating profit as % of sales
-42.6%
↑ +37.4% 2th
FCF / Share Free cash flow per share
$-0.04
↑ +66.8% —
Long-Term Debt Long-term obligations
$87.92M
↓ -5.9% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability ↑
3
Returns ↓
5
Financial Health ↑
39
Cash Quality ↓
44

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 12 years · 43 quarters